Catalyst Wire Dossier Catalyst Wire Dossier

CC-5013

lenalidomide · Celgene
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for CC-5013, covering 2013-12-17 to 2019-11-12. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 2]

See pricing